Disturbances of endometrial bleeding with hormone replacement therapy

Human Reproduction

Volumn 15, Issue , 2000, Pages 7-17

  Thomas, A M ^a   Hickey, M ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Bleeding; Blood vessels; Endometrium; Hormone replacement therapy

Indexed keywords

ALPHA ACTIN; COLLAGEN; ESTRADIOL; ESTROGEN; ESTRONE SULFATE; ETHINYLESTRADIOL; GESTAGEN; LAMININ; LEVONORGESTREL; MATRIX METALLOPROTEINASE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PLASMINOGEN ACTIVATOR; PROTEOGLYCAN; STEROID HORMONE; VASCULOTROPIN;

AMENORRHEA; ANGIOGENESIS; BREAKTHROUGH BLEEDING; CONFERENCE PAPER; DISEASE ASSOCIATION; DOSE RESPONSE; ENDOMETRIUM; ENDOMETRIUM ATROPHY; ENDOMETRIUM CARCINOMA; ESTROGEN THERAPY; HORMONE SUBSTITUTION; HUMAN; HYSTEROSCOPY; LONG TERM CARE; MICROVASCULATURE; POSTMENOPAUSE; PROTEIN EXPRESSION; QUALITY OF LIFE;

EID: 0033823889     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/15.suppl_3.7     Document Type: Article

References (46)

1. Abnormal uterine bleeding on hormone replacement: The importance of intrauterine structural abnormalities
2. Regular bleeding on hormone replacement therapy: A myth?
3. Angiogenesis in embryos and ischaemic diseases
4. Vascular permeability factor; A tumor-derived polypeptide that induced endothelial cell and monocyte procoagulation activity and promotes monocyte migration
5. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
6. Can we improve compliance with long-term HRT?
7. The predictive value of out-patient hysteroscopy in a menopause clinic
8. Correlation of endocrine profiles with bleeding patterns during use of Nestorone contraceptive implants
9. Angiogenesis
10. A review of the role of progestogens in hormone replacement therapy; influence on bleeding patterns
11. Lack of correlation between vascular endothelial growth factor production and endothelial cell proliferation in the human endometrium
12. Incidence of ovulation in perimenopausal women before and during hormone replacement therapy
13. Angiogenesis in the female reproductive tract
14. Endometrial sonographic and histologic findings in women with and without hormone replacement therapy suffering from postmenopausal bleeding
15. Compliance considerations with estrogen replacement: Withdrawal bleeding and other factors
16. Endometrial vasculature in Norplant® users: Preliminary results from a hysteroscopic study
17. Microvascular density in conditions of endometrial atrophy
18. Changes in vascular basement membrane in the endometrium of Norplant® users
19. Endometrial vascular features prior to and following exposure to levonorgestrel
20. Endometrial morphology during the normal cycle and under the influence of contraceptive steroids
21. Vascular permeability factor, an endothelial cell mitogen related to PDGF
22. The effects of levonorgestrel implants on vascular endothelial growth factor expression in the endometrium
23. Vascular endothelial growth factor is a secreted angiogenic mitogen
24. Continuous low dose oestrogen and progestogen hormone replacement therapy: A randomised trial
25. Menstruation in intraocular endometrial transplants in the rhesus monkey
26. Hysteroscopy in women with abnormal bleeding or hormone replacement therapy: A comparison with postmenopausal bleeding
27. Stromal-epithelial interaction mediates steroidal regulation of metalloproteinase expression in human endometrium
28. A simple method for determining the optimun dose of progestin in postmenopausal women receiving estrogens
29. Immunohistochemical study of endometrial microvascular basement membrane components in women using Norplant(R)
30. Quantitation of hormone replacement-induced withdrawal bleeds
31. Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel
32. Endometrial microvascular growth in normal and dysfunctional states
33. Perivascular smooth muscle and actin is reduced in the endometrium of women with progestin-only contraceptive breakthrough bleeding
34. Compliance with hormone replacement therapy (HRT) after screening for post-menopausal osteoporosis
35. Ovarian steroid-modulated stromelysin-1 expression in human endometrial stromal and decidual cells
36. Regulation of matrix metalloproteinase-9 in endometrium during the menstrual cycle and following administration of intrauterine levonorgestrel
37. Angiogenesis, vascular endothelial growth factor and the endometrium
38. An objective and subjective assessment of uterine blood loss in postmenopausal women on hormone replacement therapy
39. The prevention and treatment of endometrial pathology in post-menopausal women receiving exogenous oestrogens
40. Irregular bleeding on HRT
41. Relations between bleeding patterns, endometrial histology and oestrogen treatment in menopausal women
42. Combined continuous hormone replacement therapy; A critical review
43. Endometrial breakdown in women using Norplant is associated with migratory cells expressing matrix metalloproteinase-9 (gelatinase B)
44. The effects of oestrogens and progestogens on the postmenopausal endometriuum
45. Avoidance of endometrial hyperstimulation in estrogen-treated postmenopausal women
46. The effects of transdermal estradiol on the endometrium of postmenopausal women